Seasonal variation in COPD exacerbation rates: budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) at two ICS dose levels in the ETHOS trial
第一作者单位:[1]Pulm Res Inst Southeast Michigan, Farmington Hills, MI USA
推荐引用方式(GB/T 7714):
Ferguson G. T.,Rabe K. F.,Martinez F. J.,et al.Seasonal variation in COPD exacerbation rates: budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) at two ICS dose levels in the ETHOS trial[J].PNEUMOLOGIE.2021,75:S13-S13.doi:10.1055/s-0041-1723287.
APA:
Ferguson, G. T.,Rabe, K. F.,Martinez, F. J.,Wang, C.,Singh, D....&Dorinsky, P..(2021).Seasonal variation in COPD exacerbation rates: budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) at two ICS dose levels in the ETHOS trial.PNEUMOLOGIE,75,
MLA:
Ferguson, G. T.,et al."Seasonal variation in COPD exacerbation rates: budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) at two ICS dose levels in the ETHOS trial".PNEUMOLOGIE 75.(2021):S13-S13